YONKERS, N.Y., April 27, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents ...
YONKERS, N.Y., April 20, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), ...
A retrospective chart review interim analysis demonstrated that cefiderocol achieved clinical cure in 65% and 60% of patients with Pseudomonas aeruginosa and Acinetobacter baumannii respectively, the ...
New research being presented at this year's European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Lisbon, Portugal (23-26 April) has identified a panel of cytokines that can ...
Cidara Therapeutics Highlights New Data from Multiple Rezafungin Studies Presented at ECCMID 2019 Data featured in three oral and five poster presentations reinforce potential of novel antifungal for ...
Please provide your email address to receive an email when new articles are posted on . The European Congress of Clinical Microbiology and Infectious Diseases is taking place for the first time this ...
New Delhi: Bugworks Research Inc presented its latest research findings on the novel bacterial topoisomerase inhibitor, BWC0977 at the upcoming 33 rd European Congress of Clinical Microbiology & ...
A retrospective chart review interim analysis demonstrated that cefiderocol achieved clinical cure in 65% and 60% of patients with Pseudomonas aeruginosa and Acinetobacter baumannii respectively, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results